GlassScriptPhysician profile
Sindhu Basavaiah Igala
NPI 1265760771
$7,415.44
in general payments reported to CMS, 2019-2025
41 companies · $508 in 2025
The $508 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $1,237 · 2021: $1,352 · 2022: $1,089 · 2023: $1,445 · 2024: $1,137 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,997 · Education: $92.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,997.34 |
| Education | $92.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $826.51 | 2020-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $715.74 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $489.77 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Dexcom, INC. | $478.85 | 2019-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $434.95 | 2019-2025 | Tepezza, Prolia, Evenity |
| Lilly USA, LLC | $417.71 | 2019-2024 | Mounjaro, Jardiance |
| Abbott Laboratories | $381.89 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Tandem Diabetes Care, INC. | $379.01 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $295.40 | 2019-2024 | |
| Insulet Corporation | $284.54 | 2019-2024 | Omnipod |
| Radius Health, INC. | $282.15 | 2019-2024 | Tymlos |
| Xeris Pharmaceuticals, INC. | $244.80 | 2021-2025 | Gvoke Hypopen |
| Amarin Pharma, INC. | $233.12 | 2019-2021 | |
| Abbvie INC. | $200.97 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.86 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $124.27 | 2023-2025 | |
| Antares Pharma, INC. | $120.01 | 2020-2024 | Xyosted |
| Corcept Therapeutics | $119.67 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $115.46 | 2021-2024 | |
| Pfizer INC. | $113.08 | 2022-2024 | |
| Zealand Pharma US, INC. | $102.04 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $100.71 | 2020-2022 | |
| Medtronic, INC. | $99.34 | 2021-2024 | Minimed 780g |
| Ibsa Pharma INC. | $76.14 | 2019-2025 | Licart, Tirosint, Flector |
| Cequr Corporation | $74.03 | 2022-2024 | Cequr Simplicity |
| Beta Bionics, INC. | $73.99 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Currax Pharmaceuticals LLC | $73.79 | 2020-2023 | Nexletol |
| Grt US Holding, INC. | $73.75 | 2021-2022 | |
| Vivus LLC | $52.44 | 2019-2020 | |
| Becton, Dickinson and Company | $46.98 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $46.79 | 2021-2023 | |
| Ascendis Pharma Endocrinology INC | $36.39 | 2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $32.08 | 2020-2023 | Unithroid |
| Neurocrine Biosciences, INC. | $24.32 | 2025 | |
| Amryt Pharma Holdings LTD | $20.40 | 2023 | Mycapssa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.08 | 2022 | |
| Madrigal Pharmaceuticals | $16.36 | 2025 | Rezdiffra |
| Intuity Medical INC | $14.64 | 2022 | |
| Esperion Therapeutics, INC. | $13.11 | 2021 | |
| Nevro Corp. | $12.78 | 2023 | Senza |
| Endo Pharmaceuticals INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sindhu Igala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.